Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a severe neurodegenerative disorder characterized by the progressive degeneration of motor neurons leading to a substantial reduction in mobility, quality of life and ultimately death. The mortality rate in ALS is 50% at 18 months and most patients die within 2 to 5 years after diagnosis. There are currently no effective treatments.
ImStar therapies have the potential to treat ALS and multiple other neurodegenerative diseases expressing TDP-43 pathology such as Frontotemporal Lobular Dementia (FTLD), Alzheimer's Disease and Parkinson's Disease. The Alzheimer’s disease market alone is projected to reach $14B in annual sales by 2020 according to Decision Resources.